Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics (LCTs)
-
By
-
Abuhasanein, Suleiman
-
June 22, 2026
-
Clinical Scorecard: Exploring Oncobiotics in Bladder Cancer: A Comprehensive Review of Living Cancer Therapeutics
At a Glance
| Category | Detail |
|---|
| Condition | Urinary Bladder Cancer (UBC) |
| Key Mechanisms | Direct tumor destruction, immune system modulation, engineered drug delivery, oncolytic virotherapy, microbiome-driven immune modulation. |
| Target Population | Patients with bladder cancer, particularly those unresponsive to standard treatments. |
| Care Setting | Clinical oncology and translational research. |
Key Highlights
- High recurrence rates and limited therapeutic options for UBC.
- Living Cancer Therapeutics (LCTs) include bacteria-, virus-, and microbiome-based strategies.
- Clinical translation has progressed for immune-mediated approaches like Bacillus Calmette–Guérin (BCG).
- Most investigational platforms remain at early preclinical or translational stages.
- Significant limitations include biological delivery barriers and regulatory complexity.
Guideline-Based Recommendations
Diagnosis
Management
- Consider LCTs for patients with BCG-unresponsive UBC.
Monitoring & Follow-up
Risks
- Biological delivery barriers, host immune neutralization, interpatient heterogeneity, biosafety concerns.
Patient & Prescribing Data
Patients with urinary bladder cancer, especially those who have failed standard treatments.
Investigational therapies are at early stages; clinical evidence is limited.
Clinical Best Practices
- Further translational research and biomarker development are essential.
- Long-term clinical evaluation is required to assess the role of LCTs in UBC management.
Related Resources & Content
